InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,782.76
(
1.23%
)
US TECH 100
19,731.60
(
1.50%
)
Dow Jones
42,221.88
(
1.02%
)
Brent Oil
74.38
(
-1.34%
)
Bitcoin
74,213.76
(
7.07%
)
Post# of 253534
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 839
Posts 120670
Boards Moderated 13
Alias Born 09/05/2002

DewDiligence

Member Level

Re: jq1234 post# 126198

Wednesday, 09/07/2011 6:33:47 PM

Wednesday, September 07, 2011 6:33:47 PM

Post# of 253534
The critique of the Xarelto ROCKET-AF study is valid on strictly statistical grounds, as we had previously noted on this board (e.g. #msg-56717469). Nevertheless, I don’t for a minute believe that “skillful” use of warfarin is better for AF patients than Xarelto. This is an instance of a bad pivotal trial, not a bad drug (echoing what Dr. Pazdur once said about Erbitux).

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up